Derek Lowe's In the Pipeline blog chimes in on the Sanofi rumors. He rightly points out that no acquisition opera is ever complete until the fat lady sings. Further, it is not too wise for someone to be floating a trial balloon during an acquisition as the target's stock price invariably shoots up as does its perceived value. Doh!
Nonetheless, current names being mentioned as possible acquisition targets include Allergan, Biogen, Genzyme, and possibly Celgene or Gilead. Place your bets.
Posted by Bruce Lehr July 2nd 2010.